Inherited Metabolic Disorders: Sequencing Panel

**Test Code:** MM310  
**Turnaround time:** 6 weeks  
**CPT Codes:** 81404 x1, 81405 x1, 81406 x1

## Condition Description

Inherited metabolic disorders refer to diseases caused by defects in genes that are involved in the body’s metabolism. These usually involve the production, conversion, or use of energy. Traditionally, inherited metabolic conditions were broadly classified as disorders of carbohydrate metabolism, amino acid metabolism, organic acid metabolism, or lysosomal storage diseases. This test analyses genes involved in complex metabolic processes in the body including but not limited to the above four categories.

**Reference:**  
OMIM.

## Genes

ACAD9, ACADL, ACADM, ACADS, ACADVL, ACSF3, AGA, AGL, ALDH5A1, ARSA, ARSB, ASL, ASS1, ATPAF2, AUH, BCKDHA, BCKDHB, CD320, CLN3, CLN5, CLN6, CLN8, CPS1, CPT1A, CPT2, CYP27A1, DB1, DLD, ENO3, ETFA, ETFB, ETFDH, G6PC, GAA, GALC, GALNS, GBA, GBE1, GLA, GLB1, GMPA, GNPTAB, GYS1, GYS2, HADHA, HADHB, HGSNAT, HLC3, HMGCCL, HMGCSE2, HYAL1, IDS, IDUA, IVD, LIPA, LMBRD1, LPIN1, MAN2B1, MANBA, MCC1C, MCC2, MCEE, MCOLN1, MFSD8, MLYCD, MAA, MAB, MACHC, MADH3C, MTR, MTRR, MUT, NAGA, NAGLU, NAGS, NEU1, NPC1, NPC2, OPA3, OTC, PC, PCCA, PCCB, PKM, POLG, PPT1, PYGL, PYGM, SERAC1, SGSH, SLC17A5, SLC22A5, SLC25A13, SLC25A15, SLC25A20, SLC37A4, SLP68, SMPD1, SULCL1, SUMF1, TAZ, TMEM70, TGB1

## Indications

This test is indicated for:

- Confirmation of a clinical diagnosis of inherited metabolic disorders.

## Methodology

**Next Generation Sequencing:** In-solution hybridization of all coding exons is performed on the patient's genomic DNA. Although some deep intronic regions may also be analyzed, this assay is not meant to interrogate most promoter regions, deep intronic regions, or other regulatory elements, and does not detect single or multi-exon deletions or duplications. Direct sequencing of the captured regions is performed using next generation sequencing. The patient's gene sequences are then compared to a standard reference sequence. Potentially causative variants and areas of low coverage are Sanger-sequenced. Sequence variations are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.

**Detection**

**Next Generation Sequencing:** Clinical Sensitivity: Unknown. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions/duplications will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient's clinical/biochemical phenotype.

**Analytical Sensitivity:** ~99%.

## Specimen Requirements

Submit only 1 of the following specimen types

### Type: Whole Blood

**Specimen Requirements:**

In EDTA (purple top) tube:  
Infants (2 years): 3-5 ml  
Older Children & Adults: 5-10 ml

**Specimen Collection and Shipping:** Ship sample at room temperature with overnight delivery.

### Type: Isolated DNA

**Specimen Requirements:**

In microtainer: 60 ug

Isolation using the Qiagen™ Puregene kit for DNA extraction is recommended.

---

Disclaimer: This information is confidential and subject to change without notice. It may not be reproduced in whole or part unless authorized in writing by an authorized EGL representative.
Specimen Collection and Shipping: Refrigerate until time of shipment in 100 ng/ul of TE buffer. Ship sample at room temperature with overnight delivery.

### Related Tests

- Inherited Metabolic Disorders: Deletion/Duplication Panel